Intellectual Property Strategy and Patent Position

COVIRIX Medical has filed an International Provisional Use Patent covering the 11 different molecules of the Glucosidase inhibitor family. Our provisional patent covers the inhaled aerosol drug delivery route for these drugs which currently are not developed in man for this delivery format or route. The dose design and formulations are uniquely developed by COVIRIX and covered by our patent application.

We have been granted by the Australian patent office the Australian patent (see next slides) giving the company sole IP ownership and the same duration of IP protection as for any other new patent. We have sought additional patent grant in a number of other major countries/jurisdictions. 

By repurposing these drugs for COVID treatment, our company is able to save substantial research & development costs, in hundreds of millions of dollars, and time in years to deliver these drugs to market.